Win the Patent Cliff: How to Track Patent Expiry and Exclusivity Windows Using the FDA Orange Book
The pharmaceutical market is a system of state-sanctioned monopolies and sudden, catastrophic revenue collapses. At the center of this system […]
Insights
Own the Biologic Drug Moat: The 12-Year Monopoly Playbook
The most profitable legal monopoly in the United States does not belong to a tech giant with a locked-down ecosystem
Own the Biologic Drug Moat: The 12-Year Monopoly Playbook Read Post »
Profit From Weak Drug Patents: Identifying Weak Patent Listings in the FDA Orange Book
The U.S. Food and Drug Administration (FDA) maintains a registry that dictates the cash flow of the global pharmaceutical industry.
Profit From Weak Drug Patents: Identifying Weak Patent Listings in the FDA Orange Book Read Post »
Paragraph IV Strategy: Extracting Litigation Signals from the FDA Orange Book
The valuation of a pharmaceutical enterprise often rests less on the efficacy of its molecules than on the strength of
Paragraph IV Strategy: Extracting Litigation Signals from the FDA Orange Book Read Post »
Sell More Packaging Before Patents Die: Target drug companies shifting to OTC post-LOE
The pharmaceutical industry enters a period of unprecedented revenue contraction as the 2025-2030 patent cliff approaches. Analysis of current market
Sell More Packaging Before Patents Die: Target drug companies shifting to OTC post-LOE Read Post »
Cut Costs, Not Quality: How excipient vendors can use LOE dates to pitch cost-down excipient substitutions
The Financial Physics of Patent Cliffs The pharmaceutical sector is approaching a revenue precipice. Between 2025 and 2030, an estimated
How Abandoned Drug Patents Become Your Competitive Weapon
Every year, pharmaceutical companies abandon tens of thousands of patents and patent applications — quietly, deliberately, and in ways that
How Abandoned Drug Patents Become Your Competitive Weapon Read Post »
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff
The pharmaceutical industry is entering a $400 billion revenue transfer. Between 2025 and 2030, nearly 200 blockbuster drugs will lose
When Blockbusters Fall, Business Development Rises: Win the Patent Cliff Read Post »
Maximizing GLP-1 Market Exclusivity: Leveraging Patent Term Extension (PTE) and NCE Exclusivity to Protect Blockbuster Status
The Metamorphosis of the Global GLP-1 Market: A Strategic Overview The pharmaceutical landscape is currently undergoing a structural transformation of
